Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Toovey

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Basic & Clinical Pharmacology & Toxicology|August 8, 2008
Effect of artemisinins and amino alcohol partner antimalarials on mammalian sarcoendoplasmic reticulum calcium adenosine triphosphatase activityStephen Toovey, Leyla Y Bustamante, Anne-Catrin Uhlemann, et al.
British Journal of Clinical Pharmacology|September 11, 2018
Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian childrenTrevor N Johnson, Yumi Cleary, Neil Parrott, et al.
British Journal of Clinical Pharmacology|May 14, 2015
Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malariaBorje Darpo, Georg Ferber, Peter Siegl, et al.
Travel Medicine and Infectious Disease|May 13, 2017
Tafenoquine for malaria prophylaxis in adults: An integrated safety analysisAnne Novitt-Moreno, Janet Ransom, Geoffrey Dow, et al.
Travel Medicine and Infectious Disease|September 2, 2008
Schistosomicidal activity of the antimalarial drug, mefloquine, in Schistosoma mansoni-infected miceLuc Van Nassauw, Stephen Toovey, Joeri Van Op den Bosch, et al.
Vaccine|February 18, 2022
How frequent are acute reactions to COVID-19 vaccination and who is at risk?Nancy Dreyer, Matthew W Reynolds, Lisa Albert, et al.
International Journal of General Medicine|August 4, 2021
Identification of a Vulnerable Group for Post-Acute Sequelae of SARS-CoV-2 (PASC): People with Autoimmune Diseases Recover More Slowly from COVID-19Nancy Dreyer, Natalia Petruski-Ivleva, Lisa Albert, et al.
Travel Medicine and Infectious Disease|December 3, 2014
Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellersStephen Toovey, Keith Nieforth, Patrick Smith, et al.
American Journal of Perinatology|May 6, 2022
COVID-19 Vaccinations in Pregnancy: Comparative Evaluation of Acute Side Effects and Self-Reported Impact on Quality of Life between Pregnant and Nonpregnant Women in the United StatesEmma Brinkley, Christina DeFilippo Mack, Lisa Albert, et al.
Infection and Drug Resistance|September 12, 2022
COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine EffectivenessMatthew W Reynolds, Yiqiong Xie, Kendall B Knuth, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Basic & Clinical Pharmacology & Toxicology|August 8, 2008
Effect of artemisinins and amino alcohol partner antimalarials on mammalian sarcoendoplasmic reticulum calcium adenosine triphosphatase activityStephen Toovey, Leyla Y Bustamante, Anne-Catrin Uhlemann, et al.
British Journal of Clinical Pharmacology|September 11, 2018
Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian childrenTrevor N Johnson, Yumi Cleary, Neil Parrott, et al.
British Journal of Clinical Pharmacology|May 14, 2015
Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malariaBorje Darpo, Georg Ferber, Peter Siegl, et al.
Travel Medicine and Infectious Disease|May 13, 2017
Tafenoquine for malaria prophylaxis in adults: An integrated safety analysisAnne Novitt-Moreno, Janet Ransom, Geoffrey Dow, et al.
Travel Medicine and Infectious Disease|September 2, 2008
Schistosomicidal activity of the antimalarial drug, mefloquine, in Schistosoma mansoni-infected miceLuc Van Nassauw, Stephen Toovey, Joeri Van Op den Bosch, et al.
Vaccine|February 18, 2022
How frequent are acute reactions to COVID-19 vaccination and who is at risk?Nancy Dreyer, Matthew W Reynolds, Lisa Albert, et al.
International Journal of General Medicine|August 4, 2021
Identification of a Vulnerable Group for Post-Acute Sequelae of SARS-CoV-2 (PASC): People with Autoimmune Diseases Recover More Slowly from COVID-19Nancy Dreyer, Natalia Petruski-Ivleva, Lisa Albert, et al.
Travel Medicine and Infectious Disease|December 3, 2014
Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellersStephen Toovey, Keith Nieforth, Patrick Smith, et al.
American Journal of Perinatology|May 6, 2022
COVID-19 Vaccinations in Pregnancy: Comparative Evaluation of Acute Side Effects and Self-Reported Impact on Quality of Life between Pregnant and Nonpregnant Women in the United StatesEmma Brinkley, Christina DeFilippo Mack, Lisa Albert, et al.
Infection and Drug Resistance|September 12, 2022
COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine EffectivenessMatthew W Reynolds, Yiqiong Xie, Kendall B Knuth, et al.
Pageof 6